Revance Specifies 2016 Clinical Program Milestones
07 janv. 2016 16h05 HE
|
Revance Therapeutics, Inc
NEWARK, Calif., Jan. 07, 2016 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (NASDAQ:RVNC), a specialty biopharmaceutical company developing botulinum toxin products for use in aesthetic and...
Revance Announces Positive Phase 2 Results for RT001 Botulinum Toxin Type A Topical Gel to Treat Axillary Hyperhidrosis
23 déc. 2015 16h05 HE
|
Revance Therapeutics, Inc
NEWARK, Calif., Dec. 23, 2015 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (NASDAQ:RVNC), a specialty biopharmaceutical company developing botulinum toxin products for use in aesthetic and...
Revance Appoints Abhay Joshi, PhD, as Chief Operating Officer
14 déc. 2015 16h05 HE
|
Revance Therapeutics, Inc
NEWARK, Calif., Dec. 14, 2015 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (NASDAQ:RVNC), a specialty biopharmaceutical company developing botulinum toxin products for use in aesthetic and...
Revance Therapeutics to Participate in the 27th Annual Piper Jaffray Healthcare Conference
19 nov. 2015 16h03 HE
|
Revance Therapeutics, Inc
NEWARK, Calif., Nov. 19, 2015 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (NASDAQ:RVNC), a specialty biopharmaceutical company developing botulinum toxin products for use in aesthetic and...
Revance Therapeutics Releases Third Quarter 2015 Results
09 nov. 2015 16h03 HE
|
Revance Therapeutics, Inc
NEWARK, Calif., Nov. 9, 2015 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (NASDAQ:RVNC), a specialty biopharmaceutical company developing botulinum toxin products for use in aesthetic and...
Revance Therapeutics Announces Closing of Public Offering of Common Stock
09 nov. 2015 12h10 HE
|
Revance Therapeutics, Inc
NEWARK, Calif., Nov. 9, 2015 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC) today announced the closing of its underwritten public offering of 3,737,500 shares of its common stock at a...
Revance Therapeutics to Present at Credit Suisse 24th Annual Healthcare Conference
04 nov. 2015 16h24 HE
|
Revance Therapeutics, Inc
NEWARK, Calif., Nov. 4, 2015 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (NASDAQ:RVNC), a specialty biopharmaceutical company developing botulinum toxin products for use in aesthetic and...
Revance Therapeutics to Release Third Quarter 2015 Financial Results Monday, November 9, 2015
04 nov. 2015 16h20 HE
|
Revance Therapeutics, Inc
NEWARK, Calif., Nov. 4, 2015 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (NASDAQ:RVNC), a specialty biopharmaceutical company developing botulinum toxin products for use in aesthetic and...
Revance Therapeutics Announces Pricing of Public Offering of Common Stock
04 nov. 2015 00h20 HE
|
Revance Therapeutics, Inc
NEWARK, Calif., Nov. 4, 2015 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC) today announced the pricing of its underwritten public offering of 3,250,000 shares of its common stock at a...
Revance Therapeutics Announces Proposed Public Offering of Common Stock
02 nov. 2015 06h02 HE
|
Revance Therapeutics, Inc
NEWARK, Calif., Nov. 2, 2015 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC) today announced a proposed underwritten public offering of 3,250,000 shares of its common stock. Revance...